Clinical trials
Completed Phase 1/2 trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
393 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2002 | 1 |
| 2004 | 6 |
| 2005 | 4 |
| 2006 | 5 |
| 2007 | 9 |
| 2008 | 12 |
| 2009 | 18 |
| 2010 | 29 |
| 2011 | 19 |
| 2012 | 30 |
| 2013 | 24 |
| 2014 | 24 |
| 2015 | 27 |
| 2016 | 33 |
| 2017 | 28 |
| 2018 | 29 |
| 2019 | 23 |
| 2020 | 23 |
| 2021 | 18 |
| 2022 | 12 |
| 2023 | 14 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 393 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bristol-Myers Squibb | 21 |
| Novartis Pharmaceuticals | 18 |
| Hoffmann-La Roche | 15 |
| Banc de Sang i Teixits | 12 |
| Eli Lilly and Company | 12 |
| Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud | 10 |
| Pfizer | 9 |
| AstraZeneca | 8 |
| Clinica Universidad de Navarra, Universidad de Navarra | 6 |
| Eisai Inc. | 6 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 37 |
| Neoplasms | 31 |
| Breast Neoplasms | 25 |
| Colorectal Neoplasms | 24 |
| Melanoma | 21 |
| Neoplasm Metastasis | 16 |
| Carcinoma, Hepatocellular | 13 |
| Pancreatic Neoplasms | 13 |
| Leukemia, Myeloid, Acute | 12 |
| Multiple Myeloma | 12 |
Trials
Showing 1 to 25 of 393. Each trial links to its page on Pharma Observatory.
293 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.